Traws Pharma, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 8/100
What the filing says
Iain Dukes (CEO) and Charles Parker (CFO) issued standard Sarbanes-Oxley certifications dated August 14, 2026 for the quarter ended June 30, 2026. Both officers certified that the 10-Q contains no untrue material statements, that financial statements fairly present results, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, significant deficiencies, or fraud involving management were disclosed.
Why this rating
Routine SOX certification with no red flags; disclosure of controls and fraud findings would be more material for a $9.8M company, but absence is standard.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.